Oops, that page doesn't exist!

European cross-border HTA collaborations have much to learn from each other to keep drug prices from rising unfairly, say Nordic health technology assessment experts. Talks on HTA collaborations outside Europe are also underway.

Generics Bulletin reviews the latest regulatory developments across the world.

Regeneron’s clinical and commercial oncology leaders talk to In Vivo about making good on the company’s oncology strategy and pushing the commercial accelerator in a post-Sanofi world.

The Life Sciences Innovative Manufacturing Fund, set out in the UK budget last month, is live for applications. More UK medtechs would benefit if the cost threshold were scaled down, the industry argues.

As Sage prioritizes Zurzuvae for postpartum depression after recent setbacks, it will stop selling Zulresso for PPD and no longer pursue Zurzuvae in major depressive disorder.